Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Enhancement Technologies Holdco, Inc. (NASDAQ: RAIN) is a Nasdaq-listed company focused on ionization-based weather modification technology, including rainfall generation, snow enhancement, and fog mitigation. The RAIN news feed on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures that explain how its Weather Enhancement Technology Array (WETA) platform is being tested, deployed, and evaluated.
Investors and observers following RAIN news can expect coverage of technology trials and field results, such as reports on precipitation enhancement in international locations and early indications from U.S. installations. The company’s releases discuss peer-reviewed findings that its ionization rainfall generation systems have produced statistically significant rainfall increases in randomized trials, and they provide narrative detail on how installations are designed to influence rainfall and snowpack in water-stressed regions.
RAIN news also highlights corporate and governance developments, including appointments to the board of directors and the addition of strategic and technical advisors with backgrounds in weather modification, atmospheric science, quantum physics, and corporate governance. These items provide context on how the company is building scientific and leadership capacity as it pursues commercialization of its WETA platform.
Regulatory and listing-related updates form another important category of RAIN news. The company has issued press releases and filed Form 8-K reports describing its interactions with The Nasdaq Stock Market LLC, including prior notices about continued listing standards and subsequent confirmation that its securities are listed on the Nasdaq Capital Market under the symbols RAIN and RAINW. By reviewing this news stream, readers can track both operational progress in weather enhancement projects and key corporate milestones.
Rain Therapeutics has announced its participation in the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. The company will present three posters on its MDM2 inhibitor, milademetan, highlighting its potential as a therapeutic target. Notable presentations include the predictive biomarker for milademetan and its effectiveness in various cancers. Furthermore, Rain will host an R&D day webinar on November 9, 2021, at 11:00 am ET, discussing ongoing research and key data.
Rain Therapeutics Inc. (NasdaqGS: RAIN) is scheduled to present at the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. CEO Avanish Vellanki will lead the presentation on September 30, 2021, at 10:00 a.m. ET, which can be accessed via a webcast link or through Rain's website. The event aims to showcase Rain’s advancements in precision oncology therapeutics, including their lead product candidate, milademetan, a small molecule oral inhibitor targeting MDM2. A replay will be available on their website for 30 days after the event.
Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will present at the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. Vellanki's presentation is scheduled for September 13 at 7:00 a.m. ET. Interested parties can access the presentation via a webcast link or through the Rain website. A replay will be available for 30 days post-event. Rain focuses on precision oncology, developing therapies like milademetan, a small molecule MDM2 inhibitor, targeting various cancers.
Rain Therapeutics announced promising non-clinical data on its oral MDM2 inhibitor, milademetan (RAIN-32), at the IASLC 2021 World Conference on Lung Cancer. The findings indicate that milademetan treatment effectively targets malignant pleural mesothelioma (MPM), showcasing differential sensitivity based on genetic profiles. Increased p53 protein levels were noted in sensitive cell lines, and significant growth reduction was observed in MPM xenografts. Rain aims to address the unmet medical needs of MPM patients, particularly post anti-PD1 therapy.
Rain Therapeutics Inc. (NASDAQ: RAIN), a late-stage precision oncology firm, is presenting at the IASLC 2021 World Conference on Lung Cancer from September 8-14, 2021. The poster, titled The MDM2/p53 axis is a therapeutic vulnerability in malignant pleural mesothelioma, will be presented by Dr. Lynn Heasley on September 8. Additionally, Avanish Vellanki will participate in a Targeted Oncology Panel at the Citi 16th Annual Biopharma Conference on September 10. Recordings will be available on the Rain website post-event.
Rain Therapeutics (RAIN) has initiated the Phase 3 MANTRA clinical trial for milademetan in patients with dedifferentiated liposarcoma, marking a significant milestone achieved under a year after acquiring the program. The company reported a quarter-end cash position of $164.6 million, ensuring funding through late 2024. Despite a net loss of $8.2 million for Q2 2021, up from $2.6 million in 2020, management remains optimistic about future trials and collaborations aimed at enhancing patient outcomes and anticipate interim results from their upcoming studies.
Rain Therapeutics Inc. (NasdaqGS: RAIN) is set to release its second-quarter financial results on August 10, 2021. The management will host a conference call at 1:30 PM PT to discuss the financial outcomes and business developments. Rain Therapeutics focuses on precision oncology therapies, utilizing a tumor-agnostic strategy to select patients based on genetic profiles, with its leading candidate being milademetan (RAIN-32), an MDM2 inhibitor. Investors and stakeholders can participate in the call via dial-in or a webcast link provided in the announcement.
Rain Therapeutics has announced the commencement of a Phase 3 trial (MANTRA) evaluating milademetan (RAIN-32) in patients with de-differentiated liposarcoma (DD LPS). This pivotal study, which aims to showcase the efficacy of milademetan against the standard treatment, trabectedin, is set to involve approximately 160 patients. Notably, previous studies show that patients have experienced long-term therapy for over 4 years with milademetan, indicating a favorable safety profile. The trial focuses on progression-free survival, aiming to fulfill a significant unmet medical need.
Rain Therapeutics Inc. has announced a partnership with Tempus to enhance its Phase 2 clinical trial for RAIN-32, targeting MDM2-amplified tumors. The trial is set to commence in the second half of 2021, focusing on utilizing Tempus' genomic analysis platform for patient matching and tumor profiling. RAIN-32, an oral MDM2 inhibitor, demonstrated significant anti-tumor activity in previous trials. The company plans to initiate a pivotal Phase 3 trial for liposarcoma and a Phase 2 tumor-agnostic basket trial later this year. RAIN-32 has already received FDA Orphan Drug Designation.
Rain Therapeutics has partnered with Caris Life Sciences to enhance patient referrals for its upcoming Phase 2 clinical trial of RAIN-32, an oral MDM2 inhibitor targeting cancers with MDM2 amplification. Set to begin in H2 2021, this novel trial will leverage Caris' molecular profiling technology to identify eligible patients across various solid tumors. Additionally, RAIN-32 has shown promising antitumor activity in prior studies, leading to plans for a pivotal Phase 3 trial in liposarcoma. The FDA has granted RAIN-32 Orphan Drug Designation, underscoring its potential.